The general partner of a Luxembourg SCSp is rarely just an abstract concept in the limited partnership agreement. It is a separate legal entity, with its own corporate form, its own capital, its own governance, its own substance and its own tax profile. The way it is set up determines who signs in front of counterparties, who shoulders the unlimited-liability layer of the partnership, who holds the smaller equity slice that sits next to the limited partners, and how carried interest finds its way back to the sponsor’s team. For a Luxembourg fund, the GP setup is the structuring decision that consolidates most of the design choices the sponsor has already made on the SCSp partnership form, the RAIF wrapper and the AIFM appointment.

The framework comes from two sources. The corporate dimension of the GP — its legal form, capital, governance and substance — is governed by the Law of 10 August 1915 on commercial companies, in the version applicable to the chosen form.¹ The interaction with the partnership and the partnership’s tax treatment is governed by the SCS and SCSp regime of the same law and by Circular L.I.R. n° 14/4 of 9 January 2015 on the direct tax treatment of those partnerships.² The interaction with the AIFM perimeter is governed by the AIFM Law of 12 July 2013.³ The structuring of the GP sits at the intersection of these three frameworks.

Setup, governance and ongoing administration of the GP usually run alongside Luxembourg SPV services for private equity, company formation, Lux GAAP accounting and tax compliance. The decision points described below are the ones that come back most often during the structuring conversation with international sponsors.

1. Why a corporate GP rather than an individual

The general partner of an SCSp bears unlimited, joint and several liability for the obligations of the partnership. A Luxembourg corporate GP ring-fences that exposure within a separate legal entity, with its own balance sheet, its own governance and its own counterparty profile.

In practice, the choice between an individual GP and a corporate GP is rarely open. Institutional limited partners expect a corporate GP. Bank counterparties and depositaries treat an individual GP as a structural anomaly. The diligence frameworks used by international LPs assume a corporate layer with identifiable directors, audited accounts where applicable and a clean substance trail. An individual GP can technically work for a small partnership held by a closed group of related persons, but it does not fit the institutional Luxembourg model that sponsors raise capital into.

The corporate GP also makes carry routing, succession, transfers and removal mechanics workable. A corporate entity can be transferred, restructured, replaced or liquidated without dissolving the partnership itself, provided the LPA is drafted with the right replacement and succession clauses. An individual GP introduces personal-life risks — death, incapacity, conflicts — that the partnership and its limited partners are not equipped to absorb cleanly.

2. The choice of legal form

The SARL is the default form for a Luxembourg GP. It is fast to incorporate, has the lowest minimum capital, can be set up with a single shareholder and a single manager, and adapts well to a sponsor-controlled governance model. Its private nature also keeps the share register inside the company rather than visible on the public RCS, which suits the closed ownership of a typical sponsor entity. The SARL guide covers the broader corporate mechanics.

The SA is the institutional alternative. Some sponsors prefer it for its board structure, its ability to issue different classes of shares more flexibly, and the comfort it gives certain LPs that expect a public-limited-company-style governance layer. The SA is also the natural form when the GP itself anticipates future external shareholders, such as a senior team buy-in or a strategic investor at sponsor level. The full mechanics are set out in the SA guide.

The SCA, the partnership limited by shares, is used in narrower cases. Some sponsors design the GP itself as a commandite with a managing partner controlling governance and a limited partnership of LP-style shareholders for the team. This is a more elaborate setup, generally seen on larger or longer-running platforms. For most first funds, the SARL is the right starting point and the SA is the right step up; the SCA enters the picture when the GP layer itself has internal governance and economics complex enough to justify a partnership form.

GP corporate form	Minimum capital	Typical use case
SARL	EUR 12,000 fully paid up at incorporation	First fund, mid-market PE/VC, sponsor-controlled GP
SA	EUR 30,000 with 25% paid up at incorporation	Institutional sponsors, board-driven governance, future external shareholders
SCA	EUR 30,000 with 25% paid up at incorporation	Sophisticated platforms, GP with internal commandite economics

The SARL and the SA can both serve as GP without difficulty. The interaction with the partnership is identical from the SCSp’s point of view. The choice is therefore made on the corporate side — governance, capital, future flexibility — rather than on the partnership side.

3. Minimum capital and incorporation mechanics

The minimum capital figures sit in the 1915 law. A SARL must be incorporated with a share capital of at least EUR 12,000, fully subscribed and fully paid up at incorporation under the current rules. The SA must have a share capital of at least EUR 30,000, of which at least 25% must be paid up at incorporation, under Article 420-1 of the 1915 law.¹ The SCA follows the SA capital regime. Contributions in kind require an apporteur report; cash contributions are blocked on a Luxembourg bank account until the notary acts.

A draft bill on the modernisation of SARL incorporations was approved in first reading by the Luxembourg Parliament on 28 April 2026 and would, if enacted, allow the EUR 12,000 minimum capital of a SARL to be subscribed at incorporation but paid up over a period of up to twelve months for cash contributions only.⁴ The reform does not change the minimum amount itself and does not affect contributions in kind, which remain payable in full. Sponsors planning a SARL-form GP in the second half of 2026 should follow the legislative calendar, as the deferred-payment regime, once enacted, would change the cash-management profile of an incorporation week and the way founder liability is handled until full payment.

The incorporation itself is straightforward. A Luxembourg notary records the deed, the entity is registered with the Trade and Companies Register, and the central register of ultimate beneficial owners is updated. Banking onboarding is the practical bottleneck rather than the corporate steps, and the timetable should anticipate KYC review on the sponsor side, on the senior team side, and on the AIFM side where the GP is being set up alongside an AIFM appointment.

The GP is incorporated as a standalone Luxembourg company, then subscribes to a partnership interest in the SCSp at the time the LPA is signed. The GP’s capital therefore sits at GP level, not at SCSp level, and is decoupled from the EUR 1,250,000 minimum net assets that apply to a RAIF or to a SIF.

4. The 5% economic interest rule

The most consequential structuring point of a Luxembourg GP is its economic interest in the partnership. Under Circular L.I.R. n° 14/4 of 9 January 2015, an SCSp that qualifies as an alternative investment fund is deemed not to carry on a commercial activity, and therefore remains outside municipal business tax, only to the extent that the general partner holds an interest of less than 5% in the partnership.²

Above 5%, the safe harbour falls away. The SCSp itself becomes liable to municipal business tax at entity level. This re-introduces a layer of Luxembourg direct tax that the structure was designed to avoid, and it does so on the entire result attributable to the SCSp, not just on the GP’s share. For most sponsors and most LPs, this is a hard line that the cap table cannot cross.

The standard answer is to keep the GP’s economic interest small. The market practice is around 1% of the partnership, often a token amount calibrated to the GP’s role rather than to the deal economics. The GP’s participation is sized to reflect its function — signing authority, governance, representation — rather than to capture profit. Profit allocation to the sponsor’s team is then handled separately through the carry mechanism described below.

The 5% threshold is read as an interest in the partnership, not as a participation in the AIFM, the central administration or any other regulated function. A sponsor that holds the AIFM, the GP and the carry vehicle through one common parent does not aggregate those holdings for the 5% test. The test is specifically the GP’s interest in the SCSp itself.

5. GP economics and carry routing

A Luxembourg GP usually receives a clearly identified compensation, separate from any management fee paid to the AIFM. The two streams must be designed coherently with the LPA, the AIFM agreement and the relevant service contracts.

Management fees are typically paid by the SCSp to the AIFM, not to the GP. The GP receives a smaller, defined remuneration for its own role — directors’ fees for its board, a fee for representation and signing functions, or a profit allocation that remains within the 5% perimeter. Routing the management fee through the GP would push the GP’s economic profile beyond a pure governance role and risks compromising the safe harbour. Sponsors who manage their own AIFM keep the management fee at AIFM level and let the GP charge for the narrower set of corporate functions it performs.

Carried interest is rarely paid directly to the GP itself. Doing so forces the GP’s interest in the partnership above 5% in most plausible deployment scenarios and busts the AIF safe harbour for the entire SCSp. The standard structuring uses a separate carry vehicle that holds a profit interest in the fund. The carry vehicle is often another partnership, frequently a Luxembourg SCS or SCSp, with the senior investment team as limited partners and the sponsor as general partner. Carry then flows from the fund to the carry vehicle, and from the carry vehicle to the team members based on the LPA’s vesting and waterfall mechanics.

This routing has three consequences worth keeping in mind during structuring. The GP and the carry vehicle are separate legal layers, with separate accounts, separate governance and separate KYC profiles. The waterfall in the LPA must explicitly allocate the relevant slice of distributable proceeds to the carry vehicle, with a clean carve-out from the LP entitlements. The carry vehicle itself often follows the partnership tax-transparency logic at entity level, with the actual income tax conversation moving to the team members in their home jurisdictions. For Luxembourg-resident carry recipients, the personal-tax outcome is shaped by the carried interest regime in force since 1 January 2026, with a contractual route at one quarter of the global rate and a participation-linked route under the capital gains framework.

6. The GP-as-AIFM question

The SCSp cannot be authorised as an internally managed AIF because it has no legal personality.³ An external AIFM must therefore be appointed. Two configurations are possible. The GP itself can act as the external AIFM, in which case the GP must hold the relevant authorisation under the AIFM Law and meet the full operating, capital and substance requirements that come with it. Or a separate AIFM is appointed, either dedicated to the sponsor or operated by a third-party AIFM platform.

The dual role — GP and AIFM in one entity — is feasible, but uncommon for first funds. It concentrates risk, governance and substance requirements in a single Luxembourg vehicle. It also requires upfront investment in the regulated dimension of the AIFM at a moment when most sponsors are still scaling. The more usual route is to keep the GP as a focused signing and governance entity and to appoint a separate authorised AIFM. The GP then acts within the LPA, while the AIFM operates the AIFMD-grade regulatory layer described in the AIFM regime guide.

A sponsor that operates a single, large platform across several products may eventually merge the two functions into one entity for substance and cost reasons. That step is usually planned later in the platform’s life, once AUM, deal flow and governance have stabilised. For a first fund, the GP and the AIFM are best kept as distinct legal layers, with consistent governance across the two but separate corporate identities.

7. Substance, governance and dirigeants

The GP must have real substance in Luxembourg. A registered office, a board or managing body whose composition reflects local effective management, a place where decisions are taken and documented, and a chain of records that supports the substance claim under counterparty and tax review.

Board composition is a recurrent diligence item. The expectation, both from LPs and from regulators reading the broader fund file, is that effective management of the GP takes place in Luxembourg. That usually translates into a majority of Luxembourg-resident directors or managers, regular board meetings held in Luxembourg with proper minutes, and a documented decision trail on signing authorities, banking relationships and material LPA matters. The detail of director profiles depends on the size and complexity of the fund.

The GP’s substance must be coherent with the substance of the AIFM and with the operating model of the SCSp. A GP whose board sits abroad while the AIFM and the depositary are properly set up in Luxembourg is a structural inconsistency that LPs flag during ODD. Conversely, a robust GP board, Luxembourg-resident dirigeants and a coherent meeting cadence reinforce the broader substance file of the platform.

Domiciliation of the GP follows the general framework set out in the Luxembourg domiciliation guide, with the registered office and corporate housekeeping anchored locally. Domiciliation is a starting point, not a substitute for substance. Most LPs and most regulators look beyond the registered office to the actual decision-making layer, and that layer must be designed and run accordingly.

8. Tax treatment of the GP

The GP itself is a Luxembourg commercial company and follows the general direct tax regime applicable to its corporate form. As an SA or a SARL, the GP is fully subject to corporate income tax, municipal business tax and net wealth tax, on its own taxable basis. The GP’s taxable income consists of the remuneration it receives — directors’ fees, GP fees, ancillary services — and any gains on its own assets, less deductible expenses.

Two practical points come back regularly. The GP’s small partnership interest in the SCSp is read through the SCSp’s transparency. Where the SCSp benefits from the AIF safe harbour, the GP’s share of partnership-level income flows through to it without a Luxembourg entity-level tax at SCSp level, and the GP then treats that share within its own corporate tax computation. Treaty access is then assessed at GP level, on the basis of its corporate tax residence and substance.

The GP’s deductible costs include the operational running costs it actually bears — staff or directors’ fees, office, audit, professional fees, listing or registration costs where relevant. Where the GP outsources certain functions to other group entities, transfer pricing must be documented in line with Luxembourg general tax law. Coordination with the AIFM’s tax position, the carry vehicle’s allocations and the SCSp’s annual reporting is part of the steady tax compliance work that follows incorporation.

9. Coordination with the AIFM, the depositary and the central administration

The GP, the AIFM, the depositary and the central administration form the operating square of a typical Luxembourg fund. Each plays a distinct role and contracts separately with the SCSp, but the four roles must be designed to work together rather than as parallel silos.

The GP signs material acts on behalf of the SCSp under the LPA. The AIFM exercises portfolio management and risk management within the AIFMD framework. The depositary holds or records the assets, monitors cash flows and performs ownership verification. The central administration handles the books and records, calculates the net asset value, prepares the annual report and supports the audit. The interfaces between these four — investment committee minutes, valuation memos, NAV approvals, depositary cross-checks, board resolutions of the GP — must be consistent both with the LPA and with the AIFMD chain.

For a closed-ended PE or VC fund built around an SCSp, the practical pattern is steady. The GP convenes its board for material LPA matters, the AIFM convenes its committees for portfolio decisions, the depositary monitors the cash and asset side, and the central administration produces the books. A coherent meeting cadence and a shared file of governance documents are the practical infrastructure that allows the four roles to operate cleanly. Setup support typically connects to Luxembourg SPV services for private equity, Lux GAAP accounting and the broader operating perimeter that follows the GP’s incorporation.

10. When the GP setup needs to be revisited

A GP that was right for the first fund is not always the right structure for the third. Three signals usually trigger a structural review. AUM growth pushes the management fee, the carry profile and the substance expectations beyond what a small SARL-form GP can support cleanly. New strategies inside the platform — credit, real estate, secondaries — push toward a different governance model and sometimes toward a separate GP per fund family. A senior team rotation triggers a review of the GP’s board, the carry vehicle’s vesting and the LPA’s removal mechanics.

The corporate form is rarely the issue in those reviews. The substance file, the GP-AIFM-depositary chain, the carry routing and the cap table coherence are. A Luxembourg GP that grows with the platform is one that was set up with these questions in mind from the first incorporation, rather than one that was reverse-engineered later. That is what makes the GP setup worth its disproportionate weight in the early structuring of a Luxembourg fund.

Footnotes

1. Law of 10 August 1915 on commercial companies, including Article 420-1 on the SA minimum capital and the SARL provisions on minimum capital and incorporation mechanics. ↩ ↩²

2. Circular L.I.R. n° 14/4 of 9 January 2015 on the direct tax treatment of the SCS and the SCSp, including the AIF safe harbour from municipal business tax and the 5% GP threshold. ↩ ↩²

3. Law of 12 July 2013 on alternative investment fund managers, framing the AIFM authorisation that conditions the GP-as-AIFM option. ↩ ↩²

4. According to the Luxembourg legislator, draft bill no 8669 modernising the rules on SARL minimum-capital payment was approved in first reading on 28 April 2026 and would, if finally enacted and published in Mémorial A, allow up to twelve months of deferred payment for cash contributions only. ↩